RNAi Therapeutics 2008

RNAi Therapeutics 2008

This is the latest RNAi-based Therapeutics Market Report from Select Biosciences. This report presents an up-to-date thorough analysis of the RNAi therapeutics landscape based upon our continuing coverage of this dynamic marketplace. This report presents an exhaustive analysis of all the therapeutics areas where research efforts using RNAi-based therapeutics are being focused: From Research/Pre-Clinical through Phase III Clinical Trials. Select Biosciences proprietary market survey addresses druggability trends, drug target classes (where RNAi therapeutics will impact) and different therapeutic areas in terms of challenges/opportunities/quantitative industry metrics-this highly valuable dataset is based on an extensive market analysis.

An extensive analysis of the Intellectual Property (IP) landscape in RNAi therapeutics space, RNAi technology trends, and relevant company profiles make this report a complete and timely industry analysis.

Topics Covered in this Report

• Opportunities and challenges in the RNAi therapeutics space
• Therapeutics areas impacted by RNAi therapeutics: Timeline for impact, top-most challenge in each therapeutic area
• Different target classes and their amenability to targeting using RNAi therapeutics
• Top-most drug target class for RNAi therapeutics
• Delivery approach by therapeutic area
• Factors that determine whether a given target will be druggable via RNAi-based therapeutics
• Opportunities for vendors in the space
• Research/Pre-Clinical, Phase I, Phase II, and Phase III RNAi therapeutics Clinical Trials: Details by company, molecular target, therapeutic/disease area, partnership[s]
• Technology trends in the RNAi space
• Intellectual property (IP) in the RNAi therapeutics space: Landscape and discussion of the various key patents
• Relevant company profiles: Partnerships, therapeutics/trials pipeline

Contents

• Chapter I. Executive Summary
• Chapter II. Opportunities and Challenges In the Space
  • Chapter III. RNAi Therapeutics Market Analysis: Results of Market Survey performed by Select Biosciences to Analyze the Market Landscape
  • Geographic Distribution of the Respondent Pool
  • Affiliation of the Respondent Pool
  • Challenges Impacting RNAi Therapeutics by Therapeutic/ Disease Area
  • Top-Most Challenge by Therapeutic/ Disease Area
  • Timeline of Impact by Therapeutic Area
  • Delivery Approach by Therapeutic Area
  • Drug Target Classes amenable to RNAi Therapeutics
  • Druggability Factors
  • Factors that determine whether a given drug target will be druggable via RNAi-based therapeutics
  • Key Challenges for RNAi-based therapeutics
  • Opportunities in the RNAi-based Therapeutics marketplace -- [ie., what products/ services would be of value to the industry]
• Chapter IV. RNAi Therapeutics in Development
  • Cancer
  • Cardiac Disease
  • Immunologic Disease
  • Infectious Disease
  • Inflammation
  • Lifestyle
  • Metabolic Disease
  • Neurologic Disease
  • Opthalmic Disease
  • Renal Disease
  • Respiratory Disease
  • Appendix I. Research Methodology
  • Appendix II. Technology Trends in the RNA Interference (RNAi) Space
  • Scope
  • End-user Segmentation
  • Technologies for Inducing RNAi
  • Methods for Detecting Gene Silencing
  • Libraries of siRNAs/ shRNAs to Knock-down Genes en masse
  • Publicly-Available Large-scale Mammalian RNAi Libraries
  • The RNAi Consortium (TRC): A Cooperative Effort to
  • Generate Large Libraries for Gene Knockdown
  • Comparison of Strategies for Target Validation, Especially in the Pharmaceutical Industry
  • Market Shifts in the RNAi Space: Where is the Field Heading?
  • MicroRNA-based RNAi Interference: The Leading-Edge of the RNAi Space
  • Biological Function of microRNAs
  • Role of MicroRNAs in Cancer
  • MicroRNAs in Human Cancer: The Different Molecular Entities Identified and the Conflicting Experimental Evidence Thus Far
  • SWOT Analysis of the Various Technologies in the RNAi Space, and Vendors Commercializing These Technologies
  • Appendix III. Intellectual Property [IP] in the RNAi Therapeutics Space
  • Timeline
  • Key Founding IP
  • RNAi Patent Landscape and key claims in major patents
  • RNAi Therapeutics IP Landscape-2
• D Maps of the Space, annotated with patent filings for some of the key companies in the RNAi therapeutics space
  • Appendix IV. Relevant Company Profiles
  • Alnylam Pharmaceuticals, Inc
  • Benitec Ltd
  • Calando Pharma
  • Intradigm
  • Nastech Pharmaceutical Company, Inc
  • Nucleonics, Inc
  • Opko Corporation
  • Quark Biotech
  • RXi Pharmaceuticals
  • Santaris Pharma A/ S
  • Silence Therapeutics AG

Related products

MicroRNAs Commercial Products on the Horizon With the first diagnostics set to debut within a year, the new research and development field of microRNAs is beginning to reveal its potential. This new report establishes a baseline...

Delivering RNAi-Based Therapeutics & Diagnostics Challenges & Opportunities This cutting edge & insightful report can be used to interpret & assess the potential of RNAi-based medicines. It provides opinions & market projections to: Assess the commercial potential of RNAi-based...

RNA interference (RNAi) This report analyzes the worldwide markets for RNA interference (RNAi) in US$ Million by the following application areas: Drug Discovery and Target Validation, Reagents, and siRNA Synthesis. The report provides...

M&A trends in Pharma Introduction M&As have been the preferred growth strategy by a majority of Pharma companies. Although mega-mergers certainly create economies of scale and boost pipelines, the long-term effects may not be as...

Ribonucleic Acid (RNA) Therapeutics Strong Potential to Address Unmet Needs in Pharma GBI Research, the leading business intelligence provider, has released its latest research "Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharma", which provides insights into the...

RNAi/MicroRNA 2007 This report presents an industry analysis of the RNAi and microRNA markets in both qualitative and quantitative terms. Select Biosciences' industry tracking of these spaces involves analyses of the technology...

Intranasal Drug Delivery US Market Trends & Analysis The US intranasal drug delivery market is witnessing an expansion of therapeutic applications from the delivery of conventional local therapeutic drugs to the delivery of systemic therapeutic drugs. The future...

Huntington's Disease Therapeutics This report analyzes the Global market for Huntington's Disease Therapeutics in US$ Million. Annual estimates and forecasts are provided for the period 2009 through 2015. The report profiles 37 companies...

RNAi Therapeutics: Second-Generation Candidates Build Momentum Report Author:  Allan Haberman, PhDMany established pharma companies have entered into major deals with some of these RNAi therapeutics companies.  Also covered are companies focus on development of microRNA-based therapeutics and...

Top 10 Drug Discovery Technologies Strategic Analysis And Global Forecasts Top 10 drug discovery technologies strategic analysis and global forecasts (2010 to 2015) The top 10 drug discovery technologies play a vital role in the growth of the entire...

Gene Therapy This report analyzes the Global market for Gene Therapy in US$ Million. Annual estimates and forecasts are provided for the period 2007 through 2015. The report profiles 100 companies including...

Top Companies and Products in the RNA/DNA Therapy Products Market Forecasts: The Challenge Of Turning Technology Into Therapy Please Note: Reports are sold based on the user licenses indicated. The reports will be accessible in Flash format via an online reading room on the publisher website, allowing viewing...

The Exploding RNAi Market & Future Direction Translating the Genome into a Large Market by 2009 Since its discovery in 1998 by two scientists, the naturally occurring RNA interference effect has been hailed as the hottest technical breakthrough in biological research in the last decade. ...

Gene Therapy Worldwide Market Challenges & Opportunities Gene therapy promises to be one of the most important frontiers in medicine. Although no significant achievements for curing disease have been achieved, the future seems to hold significant potential...

Cancer Personalized Medicine 2008 This is the latest most up-to-date Cancer Personalized Medicine Market Report from Select Biosciences. This report presents an up-to-date and thorough analysis of the Cancer Personalized Medicine Marketplace based upon...

Alnylam Pharmaceuticals Inc Premium Company Profile Introduction Alnylam Pharmaceuticals's main focus is to discover and develop novel therapeutics based on RNA interference for the treatment of wide range of diseases such as ocular, central nervous system and...

Outlook for RNAi, 2007 siRNA and miRNA in biology, diagnostics and therapeutics Report overview RNAi-based screens have provided new opportunities for the discovery and validation of novel therapeutic targets in areas such as cancer and infectious diseases. Since 2005, enormous strides have...

Competitor Analysis RNA Therapeutics in Clinical Development The present Competitive Intelligence Report about RNA Therapeutics in Clinical Development provides a competitor evaluation in the field of RNA based molecules being developed in clinical studies for treatment of...

RNA Interference Markets Since its discovery, the naturally occurring RNA (ribonucleic acid) interference effect has been acclaimed as the most exciting technical breakthrough in biological research in the last decade. Some industry analysts...

Global RNAi Market Analysis RNA Interference (RNAi) has emerged as a breakthrough in the life sciences industry. It presents extensive potential in multiple areas, such as drug discovery, drug development, and therapeutic applications for...

Prostate Cancer Therapeutics A Global Market Perspective Growth in prostate cancer therapies can be attributed to the increase in number of prostate cancer incidences in men aged more than 60 years. Given the longevity of an average...

RNA Interference for Drug R&D Applications, Alliances, Companies and WW Market to 2011 This report assesses the RNA interference market for drug R&D. RNA interference (RNAi) has been hailed in the science media as the hottest technical breakthrough in bioscience in the last...

RNAi for Therapeutic Applications Market Prospects 2011-2021 How will the RNA interference (RNAi) therapies market develop this decade? Our new report shows you that emerging market's revenue potential from 2011 to 2021. You will see the commercial prospects...

Melanoma Therapeutics This report analyzes the worldwide markets for Melanoma Therapeutics in US$ Million. The report provides separate comprehensive analytics for US, and Rest of World. Annual estimates and forecasts are...

Competitor Analysis: RSV Vaccines and Therapeutics The present Competitive Intelligence Report about RSV Vaccines & Therapeutics provides a competitor evaluation in the field of prophylactic vaccines and therapeutic antibodies, small molecules and RNAi against infection with...

World Neurodegenerative Diseases Market 2009-2024 Rising neurodegenerative disease prevalence and expanding patent populations - where are the best opportunities and how can you unlock these? Our new report - World Neurodegenerative Diseases Market 2009-2024 - explains. The ageing...

View all products in this category